🚀

오늘의 열정을 계속 이어가세요!

체험은 만족하셨나요? 지식 자료를 소장하고 멋진 의료인으로 성장하세요!

Antacids | 마이메르시 MyMerci
제안하기

Antacids

NCLEX Review Guide: Acid-Reducing Medications

Overview of Acid-Reducing Medications

Classification and Mechanism of Action

  • Acid-reducing medications are classified into several categories based on their mechanism of action: Antacids, H2 Receptor Antagonists (H2RAs), Proton Pump Inhibitors (PPIs), and Cytoprotective Agents. Each class works at a different point in the acid production pathway to either neutralize existing acid or inhibit acid secretion.
  • Antacids directly neutralize gastric acid through chemical reactions, while H2RAs block histamine receptors on parietal cells to reduce acid secretion. PPIs irreversibly inhibit the hydrogen-potassium ATPase enzyme system (the "proton pump") in gastric parietal cells, providing the most potent acid suppression.

Key Points

  • PPIs are the most potent acid suppressants and can reduce gastric acid production by up to 99%.
  • H2RAs have a faster onset than PPIs but are less effective for long-term acid suppression.
  • Antacids provide rapid but short-term relief of symptoms by neutralizing existing acid.

Primary Indications

  • Acid-reducing medications are primarily indicated for gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), stress ulcer prophylaxis, and Helicobacter pylori eradication therapy. They may also be used for hypersecretory conditions like Zollinger-Ellison syndrome.
  • The selection of specific agents depends on the severity and chronicity of the condition, with antacids used for mild, intermittent symptoms while PPIs are reserved for more severe or persistent conditions requiring profound acid suppression.

Key Points

  • PPIs are first-line for erosive esophagitis and moderate to severe GERD.
  • H2RAs are appropriate for mild GERD and maintenance therapy after PUD healing.
  • H. pylori eradication typically requires combination therapy including PPIs plus antibiotics.

Antacids

Composition and Action

  • Antacids contain various combinations of aluminum hydroxide, magnesium hydroxide, calcium carbonate, and sodium bicarbonate. These compounds work by directly neutralizing hydrochloric acid in the stomach, raising the gastric pH temporarily.
  • The neutralization reaction produces water and salts, providing rapid symptom relief usually within minutes. However, the duration of action is relatively short (30-60 minutes), requiring frequent administration for sustained relief.

Key Points

  • Calcium carbonate has the highest neutralizing capacity but may cause acid rebound.
  • Aluminum-containing antacids tend to cause constipation, while magnesium-containing antacids may cause diarrhea.
  • Sodium bicarbonate can cause systemic alkalosis and is contraindicated in patients with heart failure or hypertension due to sodium content.

Nursing Considerations

  • Antacids can significantly interact with many medications by altering gastric pH or forming insoluble complexes, reducing the absorption of tetracyclines, fluoroquinolones, iron supplements, and certain antiretrovirals. Administer other medications at least 2 hours before or after antacids.
  • Monitor patients on chronic antacid therapy for electrolyte imbalances, particularly those with renal insufficiency. Aluminum accumulation can lead to osteomalacia and neurotoxicity, while excessive magnesium can cause hypermagnesemia in renal impairment.

Clinical Scenario

A 45-year-old patient with occasional heartburn self-medicates with aluminum hydroxide antacids. After two weeks of regular use, he complains of severe constipation and difficulty defecating. The appropriate nursing intervention would be to recommend a product containing both aluminum and magnesium hydroxide to balance the GI effects, educate about proper timing with other medications, and suggest evaluation for GERD if symptoms persist.

Key Points

  • Antacids should be administered 1-3 hours after meals for optimal effect.
  • Liquid formulations generally work faster than tablet forms.
  • Long-term use of antacids containing aluminum or calcium may increase risk of kidney stones.

H2 Receptor Antagonists (H2RAs)

Mechanism and Examples

  • H2RAs competitively inhibit histamine binding at H2 receptors on gastric parietal cells, reducing both basal and stimulated gastric acid secretion. Common examples include famotidine (Pepcid), ranitidine (Zantac), cimetidine (Tagamet), and nizatidine (Axid).
  • These medications can reduce gastric acid production by 70-80% and have a longer duration of action (6-12 hours) compared to antacids. They are particularly effective in suppressing nocturnal acid secretion, which is primarily histamine-mediated.

Key Points

  • Famotidine is the most potent H2RA and has fewer drug interactions than cimetidine.
  • Onset of action occurs within 30-60 minutes, with peak effect at 1-3 hours.
  • H2RAs are available in both prescription and OTC formulations, with OTC versions typically half the prescription strength.

Side Effects and Interactions

  • H2RAs generally have a favorable safety profile with infrequent side effects including headache, dizziness, diarrhea, and constipation. More serious but rare adverse effects include confusion (especially in elderly), gynecomastia (with cimetidine), and thrombocytopenia.
  • Cimetidine is a potent inhibitor of cytochrome P450 enzymes and can increase serum levels of warfarin, phenytoin, theophylline, and benzodiazepines. Famotidine and nizatidine have minimal effect on the cytochrome P450 system and are preferred when drug interactions are a concern.

Cimetidine can cause significant drug interactions by inhibiting hepatic metabolism of many medications. Always check for interactions before administration, especially with warfarin, as bleeding risk may increase substantially.

Key Points

  • Dose adjustment is necessary for all H2RAs in patients with renal impairment.
  • H2RAs can cross the blood-brain barrier and may cause CNS effects, particularly in elderly, critically ill, or renally impaired patients.
  • Tachyphylaxis (decreased response over time) may develop with continuous use of H2RAs after 2-6 weeks.

Proton Pump Inhibitors (PPIs)

Mechanism and Examples

  • PPIs irreversibly inhibit the hydrogen-potassium ATPase pump (proton pump) in gastric parietal cells, blocking the final step in acid production. Common examples include omeprazole (Prilosec), esomeprazole (Nexium), lansoprazole (Prevacid), pantoprazole (Protonix), and rabeprazole (Aciphex).
  • These medications can reduce gastric acid production by up to 99% and have a longer duration of action than H2RAs. PPIs require activation in an acidic environment to convert to their active sulfenamide form that binds covalently to the proton pump, resulting in prolonged acid suppression that extends beyond their plasma half-life.

Memory Aid: "PORE"

Remember PPI mechanism with "PORE":
P - Proton pump targeted
O - Omeprazole (prototype)
R - Requires acidic environment for activation
E - Effectively blocks final step of acid production

Key Points

  • PPIs should be taken 30-60 minutes before meals for optimal efficacy (especially breakfast).
  • Full therapeutic effect may take 1-4 days to develop as proton pumps are progressively inhibited.
  • Acid suppression persists until new proton pumps are synthesized (about 24-48 hours).

Side Effects and Long-term Concerns

  • Short-term side effects of PPIs are generally mild and include headache, nausea, abdominal pain, flatulence, and diarrhea. However, long-term use has been associated with several potential risks that require monitoring.
  • Prolonged PPI therapy may increase risk of Clostridium difficile infection, community-acquired pneumonia, vitamin B12 deficiency, hypomagnesemia, calcium malabsorption (potentially leading to osteoporosis and fractures), and chronic kidney disease. PPIs may also reduce the effectiveness of clopidogrel by inhibiting CYP2C19.

PPIs can significantly reduce absorption of medications requiring an acidic environment, including ketoconazole, iron salts, atazanavir, and erlotinib. Consider alternative acid-reducing strategies or medication timing adjustments for these patients.

Key Points

  • PPIs should not be discontinued abruptly after long-term use due to risk of rebound hyperacidity.
  • Patients on long-term PPI therapy should be monitored for magnesium levels, especially if taking diuretics.
  • PPIs may interact with medications metabolized by CYP2C19, particularly affecting clopidogrel efficacy.

Cytoprotective Agents

Sucralfate

  • Sucralfate (Carafate) is an aluminum hydroxide complex of sulfated sucrose that forms a protective barrier over ulcer sites. In an acidic environment (pH < 4), it polymerizes to create a viscous, adhesive gel that binds to proteins in the ulcer base, creating a physical barrier that protects the mucosa from acid, pepsin, and bile salts.
  • Unlike other acid-reducing medications, sucralfate does not alter gastric acid secretion. It primarily promotes ulcer healing by enhancing mucosal defense mechanisms, increasing bicarbonate and prostaglandin production, and binding epidermal growth factors.

Key Points

  • Sucralfate should be administered on an empty stomach, 1 hour before meals and at bedtime.
  • It binds to many medications, reducing their absorption; administer other medications at least 2 hours before or after sucralfate.
  • Long-term use may lead to aluminum accumulation in patients with renal impairment.

Misoprostol

  • Misoprostol (Cytotec) is a synthetic prostaglandin E1 analog that enhances mucosal defense mechanisms and inhibits gastric acid secretion. It increases bicarbonate and mucus production, improves mucosal blood flow, and stabilizes cell membranes.
  • The primary indication for misoprostol is prevention of NSAID-induced gastric ulcers in high-risk patients who require continuous NSAID therapy. It is particularly useful for patients who cannot tolerate PPIs or have contraindications to their use.

Misoprostol is CONTRAINDICATED in pregnant women (FDA Pregnancy Category X) as it can cause uterine contractions leading to miscarriage. Women of childbearing potential should have a negative pregnancy test before starting therapy and use effective contraception during treatment.

Key Points

  • The most common side effect is dose-related diarrhea (occurring in 10-30% of patients).
  • Misoprostol should be taken with food to minimize GI side effects.
  • The typical dose for NSAID-induced ulcer prophylaxis is 200 mcg four times daily.

Commonly Confused Points

Differentiating Acid-Reducing Medications

Characteristic Antacids H2 Receptor Antagonists Proton Pump Inhibitors Cytoprotective Agents
Mechanism Neutralize existing acid Block histamine stimulation of acid secretion Block final step of acid production Enhance mucosal protection
Onset of action Immediate (5-15 min) Rapid (30-60 min) Delayed (1-3 days for full effect) Gradual (days)
Duration Short (30-60 min) Moderate (6-12 hours) Long (24+ hours) Depends on dosing frequency
Acid suppression Minimal/temporary Moderate (70-80%) Profound (up to 99%) Minimal/none (sucralfate); Moderate (misoprostol)
Primary uses Occasional heartburn, mild symptoms Mild-moderate GERD, PUD Severe GERD, erosive esophagitis, H. pylori therapy NSAID-induced ulcer prevention, adjunctive therapy

Key Points

  • PPIs are the most effective for acid suppression but have the slowest onset of action.
  • H2RAs provide a good balance of rapid onset with moderate duration of action.
  • Antacids provide the fastest relief but require frequent dosing for sustained effect.

Common Misconceptions

  • Misconception: All acid-reducing medications can be taken at any time of day. Reality: PPIs should be taken 30-60 minutes before the first meal of the day for optimal efficacy, while antacids work best when taken 1-3 hours after meals when acid secretion is highest.
  • Misconception: H2RAs and PPIs can be stopped abruptly without consequences. Reality: Abrupt discontinuation after prolonged use can lead to rebound hyperacidity due to compensatory mechanisms, potentially worsening symptoms.

Memory Aid: "TAPE" for Administration Timing

T - Thirty to sixty minutes before meals for PPIs
A - After meals (1-3 hours) for antacids
P - Prior to bedtime for H2RAs (for nocturnal acid control)
E - Empty stomach for sucralfate (1 hour before meals)

Key Points

  • Unlike H2RAs, PPIs have no significant direct CNS effects since they don't cross the blood-brain barrier appreciably.
  • Antacids provide symptomatic relief but do not promote healing of ulcers or esophagitis.
  • Tachyphylaxis occurs with H2RAs but not with PPIs during long-term therapy.

Nursing Process Application

Assessment

  • Before administering acid-reducing medications, assess for relevant symptoms (heartburn, epigastric pain, regurgitation), timing of symptoms in relation to meals, exacerbating factors, and relief measures. Document the character, location, duration, and severity of pain.
  • Obtain a thorough medication history, including prescription medications, OTC products, and supplements to identify potential drug interactions. Assess for risk factors such as NSAID use, smoking, alcohol consumption, and H. pylori infection status if known.

Key Points

  • Assess for alarm symptoms (dysphagia, odynophagia, weight loss, anemia, hematemesis) that require immediate medical evaluation.
  • Document baseline renal function before initiating PPIs or H2RAs, especially in elderly patients.
  • Screen for pregnancy before administering misoprostol (contraindicated) or other acid-reducing medications.

Administration Considerations

  1. Check medication order for correct drug, dose, route, and timing.
  2. Verify patient allergies and contraindications before administration.
  3. Administer PPIs 30-60 minutes before breakfast (or the first meal of the day).
  4. Ensure enteric-coated PPI tablets/capsules are swallowed whole, not crushed or chewed.
  5. For patients with feeding tubes, use liquid formulations or properly dispersible tablets.
  6. Separate antacids and sucralfate from other medications by at least 2 hours.
  7. Document administration and monitor for therapeutic response and adverse effects.

For patients unable to swallow intact capsules, many PPI formulations can be opened and the granules mixed with acidic juices or soft foods (applesauce, yogurt). However, the granules should not be crushed as this will destroy the enteric coating and reduce efficacy.

Key Points

  • Shake liquid antacid preparations well before administering to ensure proper distribution of active ingredients.
  • For stress ulcer prophylaxis in critically ill patients, continuous infusion of PPIs may be used instead of intermittent dosing.
  • When transitioning from IV to oral PPIs, administer the first oral dose before discontinuing the IV infusion.

Patient Education

  • Educate patients about proper timing of medications, potential side effects, drug interactions, and lifestyle modifications to complement pharmacological therapy. Emphasize the importance of taking medications as prescribed, even after symptoms improve.
  • Instruct patients on non-pharmacological measures: elevating the head of the bed 6-8 inches, avoiding meals 2-3 hours before bedtime, weight loss if appropriate, and avoiding trigger foods (caffeine, chocolate, fatty/spicy foods, citrus, tomatoes, alcohol).

GERD Lifestyle Modifications: "ALERTS"

A - Avoid trigger foods (spicy, fatty, acidic)
L - Lose weight if overweight/obese
E - Elevate head of bed 6-8 inches
R - Reduce meal size (eat smaller, more frequent meals)
T - Timing (avoid eating 2-3 hours before bedtime)
S - Stop smoking and limit alcohol

Key Points

  • Warn patients about potential vitamin and mineral deficiencies with long-term PPI use (B12, magnesium, calcium).
  • Educate patients about signs/symptoms that warrant medical attention (black stools, persistent pain, difficulty swallowing).
  • Instruct patients on proper tapering of long-term acid suppressants to prevent rebound hyperacidity.

Study Tips and Self-Assessment

Quick Check Questions

1. Which medication class provides the most potent acid suppression?

2. What is the appropriate timing for PPI administration?

3. Which medication is contraindicated in pregnancy due to risk of miscarriage?

4. What is the primary concern with long-term cimetidine use?

5. Which acid-reducing medication forms a protective barrier over ulcer sites?

Common NCLEX Pitfalls

  • Confusing the timing of administration between different acid-reducing classes
  • Overlooking the need for renal dose adjustments for H2RAs
  • Missing contraindications for specific patient populations
  • Failing to recognize serious drug interactions, especially with antacids and cimetidine
  • Not identifying appropriate nursing interventions for side effect management

Self-Assessment Checklist

  • I can differentiate between the four main classes of acid-reducing medications and their mechanisms of action.
  • I understand the appropriate timing and administration considerations for each class.
  • I can identify major side effects and contraindications for each medication class.
  • I recognize important drug interactions with acid-reducing medications.
  • I can educate patients on proper use of acid-reducing medications and complementary lifestyle modifications.
  • I understand the nursing process as it relates to acid-reducing medication administration.
  • I can identify situations requiring immediate medical attention versus those appropriate for acid-reducing therapy.

Final Review Points

  • The choice of acid-reducing medication should balance efficacy, onset of action, potential side effects, and patient-specific factors.
  • Proper timing of administration is critical for maximizing therapeutic effect of all acid-reducing medications.
  • Long-term acid suppression therapy requires monitoring for potential complications and periodic reassessment of continued need.

Remember that understanding acid-reducing medications is essential for safe nursing practice across multiple clinical settings. These medications are among the most commonly prescribed and over-the-counter drugs your patients will encounter. Your knowledge of their proper use, potential complications, and patient education needs will directly impact patient outcomes and quality of care.

다음 이론을 계속 학습하려면 로그인하세요.

로그인하고 계속 학습
컨텐츠를 그만볼래?

필기노트, 하이라이터, 메모는 잘 쓰고 있어?

내보내줘
어떤 폴더에 저장할래?

컨텐츠 노트에는 총 0개의 폴더가 있어!

폴더 만들기
컨텐츠 만들기
만들기
신고했어요.

운영진이 검토할게요!

해당 유저를 차단했어요.

마이페이지에서 차단한 회원을 관리할 수 있어요.